Citadel Advisors
CGON icon

Citadel Advisors’s CG Oncology CGON Stock Holding History

Citadel Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-172,815
Closed -$11.3M – 13786
2026
Q1 		$11.7M Sell
172,815
-508,371
-75% -$28.8M ﹤0.01% 3032
2025
Q4 		$28.3M Buy
681,186
+442,414
+185% +$18.3M ﹤0.01% 1965
2025
Q3 		$9.62M Buy
238,772
+63,519
+36% +$1.85M ﹤0.01% 3336
2025
Q2 		$4.56M Sell
175,253
-963,665
-85% -$23.2M ﹤0.01% 4274
2025
Q1 		$27.9M Sell
1,138,918
-30,335
-3% -$853K 0.01% 1672
2024
Q4 		$33.5M Buy
1,169,253
+847,890
+264% +$29M 0.01% 1635
2024
Q3 		$12.1M Sell
321,363
-170,331
-35% -$5.97M ﹤0.01% 2631
2024
Q2 		$15.5M Buy
491,694
+215,233
+78% +$7.46M ﹤0.01% 2271
2024
Q1 		$12.1M Buy
+276,461
New +$11.3M ﹤0.01% 2673

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's CGON Position: Q2 2026 in Review

Citadel Advisors sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 172,815 shares — an estimated $11.3M sold.

Citadel Advisors first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $33.5M in Q4 2024. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Citadel Advisors reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 172,815 CG Oncology shares in Q2 2026, an estimated $11.3M.
  • Citadel Advisors first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
  • Citadel Advisors's CG Oncology position peaked at $33.5M in Q4 2024.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.